CureVac does not rule out expedited approval of COVID-19 vaccine by Reuters

by



[ad_1]

© Reuters. FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates coronavirus disease (COVID-19) vaccine research workflow at a Tuebingen laboratory

FRANKFURT (Reuters) – German biotech company CureVac is not ruling out a swift approval process for its future COVID-19 vaccine, its chief executive said on Sunday.

The company said on Friday that it plans to bring its vaccine to market by mid-2021. Obtaining early approval suggests the company is pushing for an earlier release date, although CEO Franz-Werner Haas has not given details on how likely it is.

“We do not rule out expedited approval, but this can only be achieved in close cooperation with the authorities,” Haas told financial site Boerse Online.

CureVac, backed by Microsoft founder and billionaire (NASDAQ 🙂 Bill Gates, listed on the Nasdaq on Friday, raised $ 213 million.

The results of recently launched clinical trials on the company’s prospective vaccine are due for release in the fall, Haas said, recalling that for now, approval is expected in the first half of next year.

CureVac is studying how to use molecules carrying a specific genetic code called messenger RNA (mRNA) to treat a range of diseases, including COVID-19.

Using messenger RNA, the researchers hope they can force a patient’s own body to create proteins that can play an important role in fighting disease.

“We see a deeper and broader understanding in the United States that the mRNA technology we use has the potential to rapidly develop an effective and efficient vaccine,” Haas said.

Warning: Fusion Media reminds you that the data contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges but rather by market makers, so prices may not be precise and may differ from the actual market price. , which means that the prices are indicative and not suitable for negotiation purposes. Therefore, Fusion Media assumes no responsibility for any business losses that you may suffer as a result of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any responsibility for loss or damage resulting from reliance on any information, including data, quotes, graphics, and buy / sell signals contained in this website. Be fully informed about the risks and costs involved in trading in the financial markets, it is one of the riskiest forms of investing possible.



[ad_2]

Source link